MX2021009702A - Metodos para tratar el dolor de la superficie ocular. - Google Patents

Metodos para tratar el dolor de la superficie ocular.

Info

Publication number
MX2021009702A
MX2021009702A MX2021009702A MX2021009702A MX2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A
Authority
MX
Mexico
Prior art keywords
ocular surface
methods
treating ocular
surface pain
treating
Prior art date
Application number
MX2021009702A
Other languages
English (en)
Inventor
Muneto Mogi
Quintus Medley
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021009702A publication Critical patent/MX2021009702A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona métodos para tratar el dolor de la superficie ocular mediante la administración de 4-(7-hidroxi-2-isopropil-4-oxo-4H-quinazolin-3-il)-benzonitrilo (compuesto I). La presente invención además proporciona métodos para tratar la enfermedad del ojo seco y la hiperemia ocular mediante la administración de 4-(7-hidroxi-2-isopropil-4-oxo-4H-qu inazolin-3-il)-benzonitrilo.
MX2021009702A 2019-02-15 2020-02-13 Metodos para tratar el dolor de la superficie ocular. MX2021009702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Publications (1)

Publication Number Publication Date
MX2021009702A true MX2021009702A (es) 2021-09-14

Family

ID=69740423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009702A MX2021009702A (es) 2019-02-15 2020-02-13 Metodos para tratar el dolor de la superficie ocular.

Country Status (15)

Country Link
US (3) US20200261456A1 (es)
EP (1) EP3923909A1 (es)
JP (1) JP2022520832A (es)
KR (1) KR20210129677A (es)
CN (1) CN113453686A (es)
AU (2) AU2020222348B2 (es)
BR (1) BR112021015998A2 (es)
CA (1) CA3130038A1 (es)
CL (1) CL2021002152A1 (es)
IL (1) IL284629A (es)
JO (1) JOP20210217A1 (es)
MX (1) MX2021009702A (es)
SG (1) SG11202107260VA (es)
TW (1) TW202045179A (es)
WO (1) WO2020165838A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CN101355946B (zh) 2005-11-04 2013-05-08 海德拉生物科学公司 调节trpv3功能的化合物
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
AU2006330883A1 (en) 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2009010529A1 (en) 2007-07-18 2009-01-22 Novartis Ag Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
EP2240467B1 (en) 2008-01-09 2013-03-20 Evotec AG Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP3515889A1 (en) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Also Published As

Publication number Publication date
IL284629A (en) 2021-08-31
WO2020165838A1 (en) 2020-08-20
US20220193078A1 (en) 2022-06-23
WO2020165838A9 (en) 2021-03-18
KR20210129677A (ko) 2021-10-28
US20200261456A1 (en) 2020-08-20
US20210275529A1 (en) 2021-09-09
CL2021002152A1 (es) 2022-04-18
CN113453686A (zh) 2021-09-28
EP3923909A1 (en) 2021-12-22
TW202045179A (zh) 2020-12-16
JP2022520832A (ja) 2022-04-01
CA3130038A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06
JOP20210217A1 (ar) 2023-01-30
AU2020222348A1 (en) 2021-08-05
SG11202107260VA (en) 2021-08-30
BR112021015998A2 (pt) 2021-10-05
US11234982B2 (en) 2022-02-01
AU2020222348B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CR20210428A (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA202191519A1 (ru) Модуляторы trex1
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP4021500A4 (en) METHOD FOR TREATING THYROID EYE DISEASE
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA202092748A1 (ru) Модуляторы экспрессии apol1
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX2021009702A (es) Metodos para tratar el dolor de la superficie ocular.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
EA202192047A1 (ru) Соединения и их применение
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202092530A1 (ru) Способы облегчения старческой астении и старения
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EP4378532A3 (en) Compounds and methods for treating fibrotic pathologies
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX2019002629A (es) Formas cristalinas de compuestos terapéuticos y usos de los mismos.